HuMax-CD20
Term · Oncology and biomedicine · MLC-T-ONC-004026
A drug used alone or with other drugs to treat certain types of chronic lymphocytic leukemia. It is also being studied in the treatment of other types of cancer. HuMax-CD20 binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. HuMax-CD20 may block CD20 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Arzerra and ofatumumab.
| Identifier | MLC-T-ONC-004026 |
|---|---|
| Field | Oncology and biomedicine |
| Expansions | Arzerra; ofatumumab |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-004026",
"term": "HuMax-CD20",
"field": "Oncology and biomedicine",
"definition": "A drug used alone or with other drugs to treat certain types of chronic lymphocytic leukemia. It is also being studied in the treatment of other types of cancer. HuMax-CD20 binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. HuMax-CD20 may block CD20 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Arzerra and ofatumumab.",
"expansions": [
"Arzerra",
"ofatumumab"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/humax-cd20/"
}
Record 8,771 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.